Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular ...

Extreme endurance running damages red blood cells in ways that may affect their ability to function properly, according to a ...

Researchers have identified a new type of blood-based biomarker test for Alzheimer's disease that measures structural changes in proteins, providing more information on the underlying biology of the ...

Rein expects to enroll patients through mid-2027, with interim data anticipated in the second half of 2026.

Human pluripotent stem-cells (HPSCs)—including human embryonic stem-cells and human induced pluripotent stem-cells—are reshaping the landscape of regenerative medicine.1,2 In Parkinson's disease, ...

In February 2026, XellSmart Pharmaceutical Co., Ltd. (XellSmart) announced that it had secured its fourth US FDA and China NMPA clearance for Phase I/II registrational clinical trial entry with its ...

ARPA-H award supports the development of an oral prodrug using Seaport’s proprietary Glyph™ platform to address dysfunctional gut lymphatics and local inflammation linked to metabolic disease and ...

CAMBRIDGE, Mass. and SINGAPORE, March 03, 2026 (GLOBE NEWSWIRE) -- Cirrus Therapeutics today announced several business and pipeline updates to support its growth as a leading global ocular immunology ...

ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology ...